Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 1.00 |
| ▸ | RAF1 | P04049 | 9/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.81 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.81 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.81 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.81 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.70 |
| ▸ | GCGR | P47871 | 2/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355176 | 1.00 | BRAF (1.00) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| Bromide SCHEMBL7648283 | 0.97 | BRAF (0.95) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL7648286 | 0.95 | BRAF (0.91) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL12856388 | 0.95 | BRAF (0.90) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL28403334 | 0.90 | MAPK13 (1.00) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL2214546 | 0.85 | BRAF (1.00) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL2649589 | 0.84 | MAPK13 (0.90) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL15075633 | 0.84 | BRAF (0.91) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL7645951 | 0.83 | MAPK13 (0.74) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL20242995 | 0.82 | RAF1 (0.70) | BRAFRAF1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| WO-2024256607-A1 | STANDARDISING PLURIPOTENT STEM CELLS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-12-19 | — | — | WO | claimed |
| CN-116036278-B | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| US-20240390373-A1 | RAF KINASE INHIBITORS FOR TREATING TUMORS HARBORING GENE FUSIONS | DAY ONE BIOPHARMACEUTICALS, INC. | 2024-11-28 | — | — | US | claimed |
| CN-118139621-A | Method for amplifying erythroid precursor cells or erythroblasts and application thereof | 北京大学 | 2024-06-04 | — | — | CN | claimed |
| US-11970713-B2 | Method for long-term ex vivo maintenance or expansion of human erythroblast, human megakaryocyte-erythroid progenitor, or human common myeloid progenitor cell and application thereof | OCGENE THERAPEUTICS CORPORATION (US) | 2024-04-30 | — | — | US | claimed |
| CN-115023495-B | Method for long-term ex vivo maintenance or expansion of human erythroblasts, human megakaryocyte-erythroid progenitors or human common myeloid progenitors and uses thereof | 奥赛金生物科技公司 | 2024-04-23 | — | — | CN | claimed |
| WO-2024011307-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | claimed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | claimed |
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | UNM RAINFOREST INNOVATIONS | 2023-06-13 | — | — | US | claimed |
| WO-2023051685-A1 | METHOD FOR AMPLIFYING ERYTHROID PROGENITORS OR ERYTHROBLASTS, AND APPLICATION THEREOF | 北京大学 | 2023-04-06 | — | — | WO | claimed |
| US-11590133-B2 | Methods and compositions for treatment of BRAF mutant cancers | MEMORIAL SLOAN KETTERING CANCER CENTER | 2023-02-28 | — | — | US | claimed |
| US-20220177842-A1 | METHOD FOR LONG-TERM EX VIVO MAINTENANCE OR EXPANSION OF HUMAN ERYTHROBLAST, HUMAN MEGAKARYOCYTE-ERYTHROID PROGENITOR, OR HUMAN COMMON MYELOID PROGENITOR CELL AND APPLICATION THEREOF | OCGENE THERAPEUTICS CORPORATION | 2022-06-09 | — | — | US | claimed |
| WO-2022120153-A1 | METHOD FOR LONG-TERM EX VIVO MAINTENANCE OR EXPANSION OF HUMAN ERYTHROBLAST, MEGAKARYOCYTE-ERYTHROID PROGENITOR, OR COMMON MYELOID PROGENITOR CELL | OCGENE THERAPEUTICS CORPORATION (US) | 2022-06-09 | — | — | WO | claimed |
| US-20150258056-A1 | USE OF miR-221 AND 222 LOWERING AGENTS TO PREVENT CARDIOVASCULAR DISEASE IN DIABETIC SUBJECTS | WOODS THOMAS COOPER (US) | 2015-09-17 | — | — | US | claimed |
| WO-2014160358-A1 | USE OF MIR-221 AND 222 LOWERING AGENTS TO PREVENT CARDIOVASCULAR DISEASE IN DIABETIC SUBJECTS | WOODS THOMAS COOPER (US) | 2014-10-02 | — | — | WO | claimed |
| JP-2002542280-A | — | — | 2002-12-10 | — | — | JP | claimed |
| EP-1173254-A2 | NOVEL TREATMENT OF NEUROTRAUMATIC CONDITIONS WITH A RAF INHIBITOR | SMITHKLINE BEECHAM PLC (GB) | 2002-01-23 | — | — | EP | claimed |
| WO-2000064422-A2 | NOVEL TREATMENT OF NEUROTRAUMATIC CONDITIONS WITH RAF INHIBITOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-11-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | BRAF 913/4885RAF1 1920/4885MAPK13 3354/4885 |
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | SOST, ACP3, KLK3 | BRAF 2583/4885RAF1 3354/4885MAPK13 2560/4885 |
| US-20240390373-A1 | RAF KINASE INHIBITORS FOR TREATING TUMORS HARBORING GENE FUSIONS | BRAF, ARAF, KRAS | BRAF 1/4885RAF1 5/4885MAPK13 1738/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | BRAF 1/4885RAF1 50/4885MAPK13 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.